Why CSL and 2 other healthcares stars could be ASX shares to buy

CSL Limited (ASX:CSL) shares are one of three in the healthcare sector that I think investors ought to consider buying right now…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Yesterday I wrote about how I'm very bullish on the tech sector over the long term due to the quality on offer inside it.

Another area of the market that I'm especially bullish on over the long term is the healthcare sector.

This is due my belief that ageing populations, increased chronic disease burden, and better technologies will lead to increasing demand for healthcare services over the next decade or two.

With that in mind, here are three healthcare shares that I think could be great long-term investments:

CSL Limited (ASX: CSL)

This global biotech giant has been one of the best and most consistent performers on the Australian share market over the last decade, delivering average earnings growth of 13.3% per annum and an average total shareholder return of 20.1% per annum. Due to its strong core business, expanding plasma collection network, and lucrative pipeline of products under development, I believe it is well placed to continue this solid form over the next decade.

Pro Medicus Limited (ASX: PME)

Although its shares trade on sky high multiples and therefore carry a lot of risk, I believe this healthcare technology company could still be a great long term investment. Pro Medicus is a leading provider of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions to healthcare organisations across the globe. There is a significant market opportunity for these systems and I expect Pro Medicus to capture a good slice of it over the long term due to the quality of its offering.

ResMed Inc (ASX: RMD)

This sleep treatment specialist's share price has fallen heavily over the last two trading sessions after its solid second quarter result still fell short of the market's lofty expectations. I believe the selloff was an overreaction and has created a buying opportunity for investors that are prepared to make a long-term investment. Especially given its leading position in a sleep treatment market expected to grow strongly over the next decade.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

two children squat down in the dirt with gardening tools and a watering can wearing denim overalls and smiling very sweetly.
Growth Shares

How to maximise $10,000 by investing in 2 ASX growth shares

Here are my best growth ideas on the ASX right now.

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

These ASX 200 growth shares could rise 50% to 60%

Big returns could be on offer from these growing companies according to analysts.

Read more »

Sports fans looking at smart phone representing surging pointsbet share price
Growth Shares

Up 111% in six months, this soaring ASX share is backed to keep rising

One fund manager thinks this ASX growth share can continue its phoenix performance.

Read more »

a happy investor with a wide smile points to a graph that shows an upward trending share price
Growth Shares

These ASX growth shares are being tipped to smash the market

Returns of 14% to 68% could be on the cards for buyers of these shares according to brokers.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Growth Shares

These ASX 200 growth shares could rise 50% to 70%

Analysts are predicting these stocks to rise materially from current levels.

Read more »

A young boy sits on his father's shoulders as they flex their muscles at sunrise on a beach
Growth Shares

2 ASX 300 growth shares with 'strong momentum' this fund manager says are buys

These two stocks have plenty of growth potential, according to experts.

Read more »

Rocket going up above mountains, symbolising a record high.
Growth Shares

2 high-growth ASX shares to buy now

Analysts at Bell Potter think these shares would be great picks for growth investors.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Growth Shares

These ASX 200 growth stocks could rise 30% to 100%

Analysts think these shares are dirt cheap at current levels and have put buy ratings on them.

Read more »